IN2012DE00661A - - Google Patents

Download PDF

Info

Publication number
IN2012DE00661A
IN2012DE00661A IN661DE2012A IN2012DE00661A IN 2012DE00661 A IN2012DE00661 A IN 2012DE00661A IN 661DE2012 A IN661DE2012 A IN 661DE2012A IN 2012DE00661 A IN2012DE00661 A IN 2012DE00661A
Authority
IN
India
Prior art keywords
substituted
hetero
aminoquinoline
aryl
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Singh Rawat Diwan
Manohar Sunny
Chinna Rajesh Ummadisetty
Original Assignee
Univ Delhi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Delhi filed Critical Univ Delhi
Priority to US14/382,727 priority Critical patent/US9567316B2/en
Priority to EP21194376.6A priority patent/EP3971178A1/fr
Priority to PT137586780T priority patent/PT2822936T/pt
Priority to ES13758678T priority patent/ES2899730T3/es
Priority to PCT/US2013/028329 priority patent/WO2013134047A2/fr
Priority to EP13758678.0A priority patent/EP2822936B1/fr
Priority to IN661DE2012 priority patent/IN2012DE00661A/en
Publication of IN2012DE00661A publication Critical patent/IN2012DE00661A/en
Priority to US15/404,964 priority patent/US11026943B2/en
Priority to US17/240,886 priority patent/US20220008418A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN661DE2012 2012-03-07 2013-02-28 IN2012DE00661A (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US14/382,727 US9567316B2 (en) 2012-03-07 2013-02-28 Aminoquinoline derivatives and uses thereof
EP21194376.6A EP3971178A1 (fr) 2012-03-07 2013-02-28 Dérivés d'aminoquinoléine et leurs utilisations
PT137586780T PT2822936T (pt) 2012-03-07 2013-02-28 Derivados da aminoquinolina e suas utilizações
ES13758678T ES2899730T3 (es) 2012-03-07 2013-02-28 Derivados de la aminoquinolina y sus usos
PCT/US2013/028329 WO2013134047A2 (fr) 2012-03-07 2013-02-28 Dérivés d'aminoquinoléine et leurs utilisations
EP13758678.0A EP2822936B1 (fr) 2012-03-07 2013-02-28 Dérivés d'aminoquinoléine et leurs utilisations
IN661DE2012 IN2012DE00661A (fr) 2012-03-07 2013-02-28
US15/404,964 US11026943B2 (en) 2012-03-07 2017-01-12 Aminoquinoline derivatives and uses thereof
US17/240,886 US20220008418A1 (en) 2012-03-07 2021-04-26 Aminoquinoline Derivatives and Uses Thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN661DE2012 IN2012DE00661A (fr) 2012-03-07 2013-02-28

Publications (1)

Publication Number Publication Date
IN2012DE00661A true IN2012DE00661A (fr) 2015-08-21

Family

ID=49117483

Family Applications (1)

Application Number Title Priority Date Filing Date
IN661DE2012 IN2012DE00661A (fr) 2012-03-07 2013-02-28

Country Status (6)

Country Link
US (3) US9567316B2 (fr)
EP (2) EP3971178A1 (fr)
ES (1) ES2899730T3 (fr)
IN (1) IN2012DE00661A (fr)
PT (1) PT2822936T (fr)
WO (1) WO2013134047A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10144932B2 (en) * 2014-06-06 2018-12-04 Board Of Trustees Of Michigan State University Nurr1 as a genetic target for treating levodopa-induced dyskinesias in Parkinson's disease
CN104070943B (zh) * 2014-07-23 2017-10-17 万通智控科技股份有限公司 一种自编程轮胎压力监测装置及实现方法
WO2016111957A1 (fr) * 2015-01-06 2016-07-14 Albert Einstein College Of Medicine, Inc. Composés triazole de chloroquinoline, composition et utilisations
CN107249588A (zh) 2015-02-16 2017-10-13 浦项工科大学校产学协力团 包含阿莫地喹作为有效成分的代谢性疾病的预防、改善或治疗用组合物
US10329258B2 (en) 2015-04-30 2019-06-25 University Of Washington CGAS in systemic lupus erythematosus (SLE)
EP3307072A4 (fr) 2015-06-15 2019-04-03 Mayo Foundation for Medical Education and Research Utilisation de cellules souches mésenchymateuses autologues pour traiter l'atrophie multisystémique
CN105301126B (zh) * 2015-10-10 2021-02-12 大道隆达（北京）医药科技发展有限公司 一种托匹司他有关物质的分析方法
EP3498279A4 (fr) 2016-08-12 2020-04-29 Novmetapharma Co., Ltd. Composition pharmaceutique comprenant comme principes actifs de l'amodiaquine et un médicament anti-diabète, destinée à la prévention ou le traitement du diabète
AU2019288490A1 (en) * 2018-06-21 2020-12-03 Nevada Research & Innovation Corporation Disease modifying methods for treating neurodegenerative diseases using nootropic agents
CN109620971A (zh) * 2018-12-14 2019-04-16 昆明医科大学第附属医院 一种筛选防治帕金森病药物的方法
BR112022003025A2 (pt) * 2019-08-22 2022-05-10 Biohaven Therapeutics Ltd Moléculas que se ligam a tdp-43 para o tratamento de esclerose lateral amiotrófica e distúrbios relacionados
WO2021087077A1 (fr) * 2019-10-29 2021-05-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibiteurs à petites molécules d'autophagie et d'histone désacétylase et leurs utilisations
CA3175047A1 (fr) * 2020-07-07 2022-01-13 The Mclean Hospital Corporation Composes et methodes de traitement de maladies neurodegeneratives
WO2022178338A2 (fr) * 2021-02-20 2022-08-25 Biohaven Therapeutics Ltd. Petites molécules qui se lient à la tdp-43 pour le traitement de la sla et de troubles apparentés
WO2023159062A2 (fr) * 2022-02-15 2023-08-24 University Of Central Florida Research Foundation, Inc. Medicaments anaboliques stimulant la production de collagene de type ii à partir de chondrocytes ou de leurs progeniteurs
WO2024049718A2 (fr) * 2022-08-31 2024-03-07 Immunocure Inc. Dérivés de quinoléine pipérazine, composition pharmaceutique et leurs utilisations

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE626239A (fr) 1961-12-29 1900-01-01
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4487761A (en) 1982-04-05 1984-12-11 Merck & Co., Inc. Dopamine β-hydroxylase inhibitors
US4992459A (en) 1983-04-12 1991-02-12 Smithkline Beecham Corporation Dopamine-β-hydroxylase inhibitors
US4906668A (en) 1984-08-23 1990-03-06 Georgia Tech Research Corporation Aminoalkyl phenyl selenides for the treatment of hypertension and nervous system dysfunctions
US4634711A (en) 1985-08-02 1987-01-06 Smithkline Beckman Corporation Pyridylalkyl imidazole-2-thiols
US4719223A (en) 1985-10-31 1988-01-12 Smithkline Beckman Corporation Imidazolethiol dopamine-beta-hydroxylase inhibitors
US4743613A (en) 1986-04-08 1988-05-10 Smithkline Beckman Corporation Ester prodrugs of dopamine-β-hydroxylase, inhibitors, composition containing them, and method of using them to inhibit dopamine-β-hydroxylase activity
US4810800A (en) 1986-05-06 1989-03-07 Merrell Dow Pharmaceuticals Inc. Novel imidazole dopamine beta hydroxylase inhibitors
US5189052A (en) 1986-05-06 1993-02-23 Merrell Dow Pharmaceuticals Inc. Thione dopamine beta hydroxylase inhibitors
US4761415A (en) 1986-08-28 1988-08-02 Smithkline Beckman Corporation Dopamine-β-hydroxylase inhibitors
US4749717A (en) 1987-01-08 1988-06-07 Smithkline Beckman Corporation Dopamine-beta-hydroxylase inhibitors
US4859779A (en) 1987-03-24 1989-08-22 Smithkline Beckman Corporation Dopamine-β-hydroxylase inhibitors
US4762850A (en) 1987-03-24 1988-08-09 Smithkline Beckman Corporation Dopamine-beta-hydroxylase inhibitors
US4835154A (en) 1987-06-01 1989-05-30 Smithkline Beckman Corporation 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors
US4798843A (en) 1987-07-09 1989-01-17 Smithkline Beckman Corporation 2-mercaproimidazole dopamine-β-hydroxylase inhibitors
US4839371A (en) 1987-09-17 1989-06-13 Smithkline Beckman Corporation 3-aralkyl-2-mercaptoyridines as dopamine-β-hydroxylase inhibitors
US4882348A (en) 1987-12-29 1989-11-21 Smithkline Beckman Corporation 2-(aminoalkylthio)imidazoles as dopamine-β-hydroxylase inhibitors
US4935438A (en) 1987-12-29 1990-06-19 Smithkline Beckman Corporation Dopamine-β-hydroxylase inhibitors
US4876266A (en) 1987-12-31 1989-10-24 Smithkline Beckman Corporation 1-aralkyl-2-mercaptoimidazolines as DBH inhibitors
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US4935449A (en) 1988-08-04 1990-06-19 Merrell Dow Pharmaceuticals Inc. N-2,3-butadienyl tri- and tetraaminoalkane derivatives
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5100912A (en) 1990-05-14 1992-03-31 Syntex (U.S.A.) Inc. Bis(benzylpyrrolidine) derivatives as dopamine agonists
US5108899A (en) 1989-10-31 1992-04-28 Exoxemis, Inc. Chemiluminescence assay of in vivo inflammation
US6559186B1 (en) 1990-02-26 2003-05-06 Arc 1, Inc. Compositions and methods of treatment of sympathetically maintained pain
CN1046723C (zh) 1993-04-06 1999-11-24 艾博特公司 四环化合物、含有它们的药物组合物及其用途
US5550139A (en) 1994-01-03 1996-08-27 The Wichita State University Serine protease inhibitors
US5925567A (en) 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
EP0934249B1 (fr) 1996-10-18 2002-03-27 Wisconsin Alumni Research Foundation Polyamines de conformation restreinte et leur utilisation en tant qu'agents antineoplasiques
US5889061A (en) 1997-10-15 1999-03-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
EA004656B1 (ru) 1999-04-01 2004-06-24 Пфайзер Продактс Инк. Аминопиримидины в качестве ингибиторов сорбитолдегидрогеназы
CA2368801A1 (fr) 1999-04-30 2000-11-09 Slil Biomedical Corporation Nouveaux conjugues d'analogue de polyamine et conjugues de quinone, utilises pour le traitement de cancers et de maladies de la prostate
CA2371625C (fr) 1999-04-30 2012-04-17 Slil Biomedical Corporation Analogues de polyamine a conformation restreinte utilises pour traiter des maladies
US7455983B2 (en) 2000-01-11 2008-11-25 Geron Corporation Medium for growing human embryonic stem cells
CA2417064A1 (fr) 2000-08-02 2002-02-07 Slil Biomedical Corporation Composes de polyamine cyclique pour la cancerotherapie
WO2003012040A2 (fr) 2001-07-27 2003-02-13 Baylor College Of Medecine Gene nurr1 mutant implique dans la maladie de parkinson
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
WO2003070244A1 (fr) 2002-02-22 2003-08-28 Abbott Laboratories Antagoniste des effets d'une hormone de concentration de melanine et son utilisation
RU2005102004A (ru) * 2002-06-27 2005-10-20 Шеринг Акциенгезельшафт (De) Замещенные хинолины как антагонисты рецептора ccr5
US7899888B2 (en) * 2002-06-28 2011-03-01 Oracle America, Inc. Runtime versioning of information processing systems
US7125904B2 (en) 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
EP1635763B1 (fr) 2003-06-09 2012-08-08 Alnylam Pharmaceuticals Inc. Procede de traitement de maladie neurodegenerative
JP2009527478A (ja) * 2006-02-16 2009-07-30 ザ マクレーン ホスピタル コーポレーション パーキンソン病の治療のための方法と組成物
WO2008036374A2 (fr) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogreffes de cellules souches chez des receveurs non conditionnes
US20110045100A1 (en) 2008-03-05 2011-02-24 Georgetown University Antimalarial Quinolines and Methods of Use Thereof
US8628962B2 (en) 2008-11-18 2014-01-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Differentiation of stem cells into dopaminergic cells
US8658648B2 (en) * 2008-12-05 2014-02-25 Designmedix, Inc. Modified chloroquines with single ring moiety or fused ring moiety

Also Published As

Publication number Publication date
PT2822936T (pt) 2021-12-02
US20220008418A1 (en) 2022-01-13
WO2013134047A2 (fr) 2013-09-12
US20170209441A1 (en) 2017-07-27
EP3971178A1 (fr) 2022-03-23
US11026943B2 (en) 2021-06-08
EP2822936B1 (fr) 2021-09-08
ES2899730T3 (es) 2022-03-14
WO2013134047A3 (fr) 2013-10-31
US9567316B2 (en) 2017-02-14
EP2822936A2 (fr) 2015-01-14
US20150023930A1 (en) 2015-01-22
EP2822936A4 (fr) 2016-04-20

Similar Documents

Publication Publication Date Title
IN2012DE00661A (fr)
PH12015502047A1 (en) Novel pyrimidine and pyridine compounds and their usage
MA34389B1 (fr) Nouvelles aminopyrazoloquinazolines
EP3670496A3 (fr) Inhibiteurs de acc2
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
SG195289A1 (en) Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
MX2015012815A (es) Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina 2,3-disustituidos y su uso como inhibidores de bromodominio.
PH12015500347A1 (en) 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MD4575C1 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
NZ705313A (en) Novel 4,6-disubstituted aminopyrimidine derivatives
CR20150268A (es) Compuestos novedosos
IN2014CN03976A (fr)
MX347241B (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
MX2013006925A (es) Compuestos de anillo indeno-fusionados.
BR112012029647A2 (pt) novos derivados de pirimidinas
PH12016500480B1 (en) Antibacterial 2h-indazole derivatives
PH12015501571A1 (en) Process for preparing the anti-tumor agent 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and its crystalline
EA201591105A1 (ru) ПИРИМИДО[4,5-b]ХИНОЛИН-4,5-(3H,10H)-ДИОНЫ В КАЧЕСТВЕ СУПРЕССОРОВ НОНСЕНС МУТАЦИЙ
MX368882B (es) Proceso para la preparacion de triazinas.
EA201692305A1 (ru) Антибактериальные хиназолин-4(3н)-оновые производные
PH12020550905A1 (en) Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives
MX353190B (es) Derivados de isoquinolina y naftiridina.
MX2016000621A (es) Proceso mejorado para preparar bifenilanilidas y bifenilanilinas cloradas.
MD4793B1 (ro) Noi compuşi de izoindolină sau izochinolină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin